Arcturus Therapeutics Holdings Inc. current report, 26 July 2019

Full document

Arcturus Therapeutics Holdings Inc. — Form 8-K Summary

Business context and reporting period

Arcturus Therapeutics Holdings Inc. filed a current report on July 29, 2019, reporting events occurring on July 26, 2019. The filing concerns amendments to and termination of agreements with CureVac AG related to development, licensing, and commercialization activities.

Key financial and operating metrics

  • CureVac agreed to make a one-time payment of $4.0 million to Arcturus in connection with terminating the co-development arrangement.
  • The payment was required to be made by July 31, 2019.
  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other period-specific financial metrics.

Material changes versus the prior arrangement

  • The parties amended the Development and Option Agreement to modify the period during which CureVac could select potential targets for licensing.
  • The maximum number of targets available for reservation and licensing was reduced from 15 to 10.
  • The target-selection and reservation process was simplified.
  • The amendment established conditions under which Arcturus could pre-restrict targets for its own research and development activities.
  • CureVac’s original obligations to fund scientists at Arcturus were restored.
  • The parties terminated the January 1, 2018 Co-Development and Co-Commercialization Agreement, including CureVac’s co-development of ARCT-810 for ornithine transcarbamylase deficiency.

Outlook, risks, contingencies, and unusual items

The $4.0 million termination payment is an unusual one-time item. Termination may affect the development and commercialization path for ARCT-810 and other collaborative programs. The filing does not provide revised financial guidance, development timelines, or commercialization expectations.

The Termination Agreement includes mutual releases and mutual non-disparagement provisions. Confidentiality obligations under the terminated agreement survive. The detailed amendment and termination provisions were to be filed as exhibits to Arcturus’s Form 10-Q for the quarter ended June 30, 2019.

Facts investors should verify

  • Whether the $4.0 million payment was received by the required July 31, 2019 deadline and how it was accounted for.
  • The detailed terms of the amendment and termination agreements once filed with the Form 10-Q.
  • The impact of CureVac’s withdrawal from co-development of ARCT-810 on clinical development, funding, and timelines.
  • The remaining targets, economics, and obligations under the amended Development and Option Agreement.
  • Any subsequent guidance regarding collaboration revenue, operating cash needs, and the company’s development pipeline.